Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
Commentary|Videos|May 23, 2025
How AI Lowers the Real-World Barriers to Trial Participation
Author(s)Andy Studna, Senior Editor
In this video interview, Michel van Harten, MD, CEO, myTomorrows, discusses how patient education and remote monitoring can help with reducing the burden of trial participation.
Advertisement
In a recent video interview with Applied Clinical Trials, Michel van Harten, MD, CEO, myTomorrows, discussed the integration of artificial intelligence (AI) in clinical trials, highlighting its potential to reduce costs, accelerate timelines, and improve inclusion. Looking forward, advancements with AI are expected to speed up drug discovery, predict drug efficacy, and develop digital twins for personalized treatment simulations, potentially reducing trial risks and costs.
ACT: While there is potential for AI in operational aspects of trials, how can it benefit the patients participating in them?
van Harten: I think it's important to lowering the barrier to actually identify and access options, and by educating them in a patient-friendly way, in their own language, and educate them. I think it's also important to support more remote monitoring to lower logistical barriers and reduce overall impact so that patients don't have to travel that much, etc. and lower the impact of participating into a trial.
Advertisement
Related to this article
In this video interview, Saamir Pasha and Carole Berini, PhD, of Ontada, explain how building trust into the data foundation—through source lineage, standardization, and reconciliation—is what makes reliable real-world evidence generation in oncology possible.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, offers practical guidance for clinical operations teams beginning their AI journey—making the case that the tools are more accessible than many assume and that waiting to start is a competitive risk in itself.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is shifting trial risk management from reactive to proactive—enabling sponsors to pressure-test protocols and anticipate pivots before a single patient is enrolled.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, walks through the categories of hidden protocol risk that AI-driven simulations can identify—from overly restrictive eligibility criteria to patient dropout patterns and structural trial assumptions.
Real-time clinical trials require standardized digital data capture at the point of care through scaled eSource-EDC-EHR integration, but progress stalls because competing standards lack regulatory enforcement and one-off system integrations cannot scale beyond single studies without industry-wide alignment and legal clarity on data ownership.
In this Q&A, Claire Riches, VP of clinical solutions at Citeline, discusses how AI is transforming endpoint selection and protocol pressure-testing, what data inputs matter most for realistic enrollment planning, and why the tools are more accessible than most sponsors assume.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
IgniteData and RealTime Partner to Streamline Clinical Data Transfer From eSource to Sponsor Systems
2
The Biggest Remaining Barriers to High-Quality RWE Across Oncology Data Platforms
3
ACT Brief: Design Drivers of Trial Representation, eSource-to-EDC Data Automation, and Roche's ALK7 Obesity License
4
Beyond Outreach: Structural Drivers of Representation in Clinical Trials
5